Regeneron Pharmaceuticals recently received U.S. FDA approval and a positive opinion from the European Medicines Agency's ...
The FDA has handed out the first nine national priority vouchers, positioning companies including Merck KGaA, Regeneron and ...
The Commissioner’s National Priority Voucher awards companies that align with specific national priorities—such as boosting ...
A gene therapy from Regeneron, a pancreatic cancer medicine from Revolution Medicines and a porphyria drug from Disc Medicine ...
In the U.S., the generic name for Libtayo in its approved indications is cemiplimab-rwlc, with rwlc as the suffix designated in accordance with Nonproprietary Naming of Biological Products Guidance ...
Six years since the FDA blessed Sanofi and Regeneron’s Dupixent as the first biologic to treat chronic rhinosinusitis with ...
It appears problems at Novo Nordisk’s recently acquired manufacturing facility in Indiana aren’t going to be solved any time ...
Study results published in The New England Journal of Medicine show the therapy significantly improved hearing in nearly a ...
Regeneron Pharmaceuticals said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended expanded approval of its blockbuster cancer drug Libtayo for certain ...
The FDA in June launched the new Commissioner's National Priority Voucher pilot program under which it could issue vouchers ...
The U. Food and Drug Administration has approved Amgen and AstraZeneca's drug for a type of chronic inflammatory sinus ...
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback